Based on the analysis performed on patient biopsies, we anticipate that ~30% of all melanoma patients without response or with relapse after ICB therapy will express high levels of TYRP1 and will be eligible for the TYRP1 CAR-T cell clinical trial. This evidence concerns the gene TYRP1 and melanoma.